Abstract
Objective
To assess the use of lipid-lowering therapy in patients with known coronary heart disease (CHD), cerebrovascular disease or diabetes in a community-based population in Sweden considering expert recommendations.
Methods
A random sample of individuals aged ≥40 years who were surveyed in 1993–1994 were revisited 10 years later during 2003–2004 (n = 724). A clinical investigation focused on cardiovascular risk including serum total cholesterol. Information on medical history and current medication was collected in structured interviews.
Results
Eighty-two patients (11.3%) reported a history of CHD, including 51 men and 31 women. Fifty-three patients fulfilled criteria for treatment and most of them (85%) were on lipid-lowering therapy. A higher fraction of women were treated; however only 13% of them reached target cholesterol levels compared to 37% of the men (P < 0.001). Sixty-five subjects (9.0%) had diabetes and/or a previous stroke (29 men, 36 women) but no previous CHD. Patients with CHD were more likely to be treated compared to patients with diabetes and/or stroke but no CHD (85.0 vs. 28.5%, OR 6.0, 95% CI 2.2–16.9, P = 0.01). In a total of 79 participants (10.9%) who were on lipid-lowering therapy, women reached a total serum cholesterol level below 5.0 mmol/L less often than men (26.3 vs. 63.4%, P < 0.001).
Conclusions
A considerable proportion of patients in primary care were untreated despite current guidelines on lipid-lowering therapy. Treatment outcome in women was less efficient compared with men. Strategies to improve pharmacological treatment in these patients should be developed.
Similar content being viewed by others
References
Wilson P, D’Agostino R, Levy D, Belanger A, Silbershatz H, Kannel W (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837–1847
Austin M, Hokanson J, Edwards K (1998) Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 81:7B–12B
Gordon D, Probstfield J, Garrison R, Neaton J, Castelli W, Knoke J et al (1989) High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 79:8–15
Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet 334:1383–1389
Medical Products Agency (1995) Treatment of hyperlipidemia. Information från Läkemedelsverket 3:95
Medical Products Agency (2003) New guidelines for treatment with lipid lowering drugs. Information från Läkemedelsverket 14:4
Hartz I, Eggen A, Grimsgaard S, Skjold F, Njolstad I (2004) Whom are we treating with lipid-lowering drugs? Are we following the guidelines? Evidence from a population-based study: the Tromso Study 2001. Eur J Clin Pharmacol 60:643–649
Cooke C, Hammerash WJ (2006) Retrospective review of sex differences in the management of dyslipidemia in coronary heart disease: an analysis of patient data from a Maryland-based health maintenance organization. Clin Ther 28:591–599
Heart Protection Study Collaborative Group (2002) Heart Protection Study of Cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7–22
Sigurdsson EL, Thorgeirsson G (2003) Primary prevention of cardiovascular disease. Scand J Prim Health Care 21:68–74
Pilote L, Ho V, Lavoie F, Coupal L, Zowall H, Grover SA (2005) Cost-effectivenes of lipid lowering treatment according to lipid level. Can J Cardiol 21:681–687
Shepherd J, Blauw G, Murphy M, Bollen E, Buckley B, Cobbe S et al (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360:1623–1630
Mungal M, Gaw A, Shepard J (2003) Statin therapy in the elderly: does it make good clinical and economic sense? Drugs Aging 20:263–275
Third Joint Task Force of European and Other Societies on Cardiovascular Diseases (2003) Prevention in clinical practice. Eur Heart J 24:1601–1610
Bog-Hansen E, Lindblad U, Bengtsson K, Ranstam J, Melander A, Råstam L (1998) Risk factor clustering in patients with hypertension and NIDDM: the Skaraborg Hypertension Project. J Int Med 243:223–232
Bengtsson K, Orho-Melander M, Lindblad U, Melander O, Bog-Hansen E, Ranstam J et al (1999) Polymorphism in the angiotensin converting enzyme but not in the angiotensinogen gene is associated with hypertension and type 2 diabetes: the Skaraborg Hypertension Project. J Hypertens 17:1569–1575
Miller M, Byington R, Hunninghake D, Pitt B, Furberg C (2000) Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada. Arch Intern Med 160:343–347
Petrella J, Merikle E, Jones J (2007) Prevalence and treatment of dyslipidemia in Canadian primary care: a retrospective cohort analysis. Clin Ther 29:742–750
Sgadari A, Incalzi R, Onder G, Pedone C, Gambassi G (2000) Lipid-lowering therapy in patients with coronary artery disease: sex or age bias? Arch Intern Med 160:2684–2685
Gibson D, Bron N, Richens A, Hounslow N, Sedman A, Whitfield L (1996) Effect of age and gender on pharmacokinetics of atorvastatin in humans. J Clin Pharmacol 36:242–246
Nakajima K, for the S-Polis Group (1999) Sex-related differences in response of plasma lipids to simvastatin: the Saitama postmenopausal lipid intervention study. Clin Ther 21:2047–2057
Bog-Hansen E, Lindblad U, Ranstam J, Melander A, Råstam L (2002) Antihypertensive drug treatment in a Swedish community: Skaraborg Hypertension and Diabetes Project. Pharmacoepidemiol Drug Saf 11:45–54
Wallenius S, Peura S, Klaukka T, Enlund H (1996) Who is using antihypertensive drugs? A prescription analysis from Finland. Scand J Prim Health Care 14:54–61
Larsson CA, Gullberg B, Merlo J, Rastam L, Lindblad U (2005) Female advantage in AMI mortality is reversed in patients with type 2 diabetes in the Skaraborg Project. Diabetes Care 28:2246–2248
Sigurdsson EL, Jónsson JS, Thorgeirsson G (2002) Medical treatment and secondary prevention of coronary heart disease in general practice in Iceland. Scand J Prim Health Care 20:10–15
Marz W, Wollschlager H, Klein G, Neiss A, Wehling M (1999) Safety of low-density lipoprotein cholesterol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial). Am J Cardiol 84:7–3
Malhotra H, Goa K (2001) Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. Drugs 61:1835–1881
Acknowledgements
We are most grateful to all those residents in Skara who participated in this study and to Mrs Ann Segerblom and Mrs Birgitta Lindberg for valuable technical assistance.
Author information
Authors and Affiliations
Corresponding author
Additional information
This research was funded by the Swedish Medical Research Council, Skaraborg Institute, Skaraborg Primary Care, Health and Medical Care Executive Board of the Region Västra Götaland, NEPI foundation, Lund University Faculty of Medicine, and Malmö University Hospital.
Rights and permissions
About this article
Cite this article
Mehner, A., Lindblad, U., Råstam, L. et al. Cholesterol in women at high cardiovascular risk is less successfully treated than in corresponding men. Eur J Clin Pharmacol 64, 815–820 (2008). https://doi.org/10.1007/s00228-008-0482-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-008-0482-x